The Influence of Cholestasis on CA 50 and CA 242 in Pancreatic Cancer and Benign Biliopancreatic Diseases

References

• Lindholm L, Holmgren J, Svennerholm L. Monoclonal antibodies against gastrointestinal tumourassociated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 1983; 71: 178–81
   PubMedGoogle Scholar
• Månsson J E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antiboty C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834: 110–7
   PubMed Web of Science ®Google Scholar
• Nilsson O, Månsson J E, Lindholm L, Holmgren J, Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett 1985; 182: 398–402
   PubMed Web of Science ®Google Scholar
• Haglund C, Kuusela P, Jalanko H, Roberts P J. Serum CA50 as a tumor marker in pancreatic cancer: a comparison with CA 19–9. Int J Cancer 1987; 39: 477–81
   PubMed Web of Science ®Google Scholar
• Paganuzzi M, Onetto M, Marroni P. CA 19–9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61: 2100–8
   PubMed Web of Science ®Google Scholar
• Benini L, Cavallini G, Zordan D. A clinical evaluation of monoclonal (CA 19–9, CA 50, CA 12–5), and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61–6
   PubMed Web of Science ®Google Scholar
• Kuusela P, Haglund C, Roberts P J. Comparison of a new tumour marker CA242 with CA 19–9, CA 50 and car-cinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991; 63: 636–40
   PubMed Web of Science ®Google Scholar
• Masson P, Pålsson B, Andrén-Sandberg Å. Evaluation of CEA, CA 19–9, CA-50, CA-195 and TATI with special reference to pancreatic disorders. Int J Pancreatol 1991; 8: 333–44
   PubMedGoogle Scholar
• Nilsson O, Johansson C, Glimelius B. Sensitivity and specificity of CA 242 in gastro-intestinal cancer. A comparison with CEA, CA 50 and CA 19–9. Br J Cancer 1992; 65: 215–21
   PubMed Web of Science ®Google Scholar
• Haglund C, Roberts P J, Kuusela P. Tumour markers CA 19–9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27: 169–74
   PubMed Web of Science ®Google Scholar
• Johansson C. C242 and other monoclonal antibodies defining novel human colorectal carcinoma associated epitopes [dissertation]. University of Gothenburg, Gothenburg 1991
   Google Scholar
• Johansson C, Nilsson O, Baeckström D, Jansson E L, Lindholm L. Novel epitopes on the CA 50-carrying antigen: chemical and immunological studies. Tumor Biol 1991; 12: 159–70
   PubMed Web of Science ®Google Scholar
• Johansson C, Nilsson O, Lindholm L. Comparison of serological expression of different epitopes on the CA 50-carrying antigen CanAg. Int J Cancer 1991; 48: 757–63
   PubMed Web of Science ®Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Ann Rev Biochem 1982; 51: 531–54
   PubMed Web of Science ®Google Scholar
• Thomas P, Zamcheck N. Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA). Dig Dis Sci 1983; 28: 216–24
   PubMed Web of Science ®Google Scholar
• Albert M B, Steinberg W M, Henry J P. Elevated serum levels of tumor marker CA 19–9 in acute cholangitis. Dig Dis Sci 1988; 33: 1223–5
   PubMed Web of Science ®Google Scholar
• Malesci A, Tommasini M A, Bonato C. Determination of CA 19–9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92: 60–7
   PubMed Web of Science ®Google Scholar
• Tatsuta M, Yamamura H, Iishi H. Values of CA 19–9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985; 56: 2669–73
   PubMed Web of Science ®Google Scholar
• Koprowski H, Herlyn M, Steplewski Z. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957–72
   PubMedGoogle Scholar
• Barone D, Onetto M, Conio M. CA 19–9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 1988; 3: 95–100
   PubMedGoogle Scholar
• Del Favero G, Fabris C, Plebani M. CA 19–9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57: 1576–9
   PubMedGoogle Scholar
• Haglund C, Roberts P J, Kuusela P, Scheinin T M, Mäkelä O, Jalanko H. Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197–202
   PubMedGoogle Scholar
• Haglund C, Lindgren J, Roberts P J, Kuusela P, Nordling S. Tissue expression of the tumour associated antigen CA 242 in benign and malignant pancreatic lesions. A comparison with CA50 and CA 19–9. Br J Cancer 1989; 60: 845–51
   PubMedGoogle Scholar
• Schwenk J, Makovitzky J. Tissue expression of the cancer-associated antigens CA 19–9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol 1989; 5: 85–98
   PubMedGoogle Scholar
• Haglund C, Lindgren J, Roberts P J. Difference in tissue expression of tumour markers CA 19–9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma. Br J Cancer 1991; 63: 386–9
   PubMedGoogle Scholar
• Ohshio G, Manabe T, Watanabe Y. Comparative studies of DU-PAN-2, carcinoembryonic antigen and CA 19–9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85: 1370–6
   PubMed Web of Science ®Google Scholar
• Ohshio G, Manabe T, Tamura K. Effects of percutaneous transhepatic drainage on blood-bile permeability and selective IgA transport in patients with biliary obstructions. Ann Surg 1990; 211: 428–32
   PubMedGoogle Scholar